Physician profile
Katherine Kwon
NPI 1891907770
$111,419.02
in general payments reported to CMS, 2019-2025
11 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.25 · 2020: $43.11 · 2022: $19.69 · 2023: $2,347 · 2024: $77K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $12K · Grant: $6,575 · Food and Beverage: $2,530 · Education: $24.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,165.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,350.00 |
| Travel and Lodging | $11,679.14 |
| Grant | $6,575.00 |
| Food and Beverage | $2,530.25 |
| Education | $24.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $90,892.43 | 2019-2025 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,306.58 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $5,479.14 | 2025 | |
| Calliditas Therapeutics US INC. | $3,055.21 | 2024 | |
| Akebia Therapeutics INC | $2,420.00 | 2024 | Vafseo, Auryxia |
| Amgen INC. | $131.37 | 2024 | Aranesp |
| Novo Nordisk INC | $52.81 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Avenu Medical INC. | $43.11 | 2020 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Nxstage Medical, INC. | $15.60 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.